Sera Prognostics, Inc. SERA
We take great care to ensure that the data presented and summarized in this overview for SERA PROGNOSTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SERA
View all-
Baker Bros. Advisors LP New York, NY5.5MShares$16.3 Million0.24% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.03MShares$8.98 Million0.23% of portfolio
-
Interwest Venture Management CO2.42MShares$7.15 Million21.78% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.65MShares$4.89 Million1.65% of portfolio
-
Black Rock Inc. New York, NY1.41MShares$4.17 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.28MShares$3.78 Million0.0% of portfolio
-
Abrdn PLC1.24MShares$3.67 Million0.01% of portfolio
-
Awm Investment Company, Inc. New York, NY867KShares$2.57 Million0.51% of portfolio
-
Jpmorgan Chase & CO New York, NY719KShares$2.13 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA634KShares$1.88 Million0.0% of portfolio
Latest Institutional Activity in SERA
Top Purchases
Top Sells
About SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Insider Transactions at SERA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 07
2025
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
234
-0.4%
|
$468
$2.36 P/Share
|
|
Jun 23
2025
|
Dyaarl Lee Anderson Jr. Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,114
+50.0%
|
-
|
|
Jun 10
2025
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,439
-0.85%
|
$1,439
$1.48 P/Share
|
|
Jun 10
2025
|
Benjamin Jackson General Counsel |
SELL
Open market or private sale
|
Direct |
965
-0.71%
|
$965
$1.48 P/Share
|
|
Jun 10
2025
|
Zhenya Lindgardt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,344
-0.4%
|
$3,344
$1.48 P/Share
|
|
Jun 10
2025
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
667
-0.58%
|
$667
$1.48 P/Share
|
|
Jun 10
2025
|
Paul Kearney Chief Data Officer |
SELL
Open market or private sale
|
Direct |
1,311
-0.67%
|
$1,311
$1.48 P/Share
|
|
Jun 10
2025
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
945
-0.32%
|
$945
$1.48 P/Share
|
|
Jun 09
2025
|
Zhenya Lindgardt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,042
-2.66%
|
$23,042
$1.43 P/Share
|
|
Jun 09
2025
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,735
-1.89%
|
$5,735
$1.43 P/Share
|
|
Jun 06
2025
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
107
-0.18%
|
$107
$1.58 P/Share
|
|
Jun 05
2025
|
Joshua Phillips |
BUY
Grant, award, or other acquisition
|
Direct |
15,596
+21.48%
|
-
|
|
Jun 05
2025
|
Ryan Trimble |
BUY
Grant, award, or other acquisition
|
Direct |
15,596
+40.71%
|
-
|
|
Jun 05
2025
|
Jane F Barlow |
BUY
Grant, award, or other acquisition
|
Direct |
15,596
+40.71%
|
-
|
|
Jun 05
2025
|
Sandra Aj Lawrence |
BUY
Grant, award, or other acquisition
|
Direct |
15,596
+40.71%
|
-
|
|
Jun 05
2025
|
Gregory C Critchfield |
BUY
Grant, award, or other acquisition
|
Direct |
15,596
+1.86%
|
-
|
|
Jun 05
2025
|
Kim P. Kamdar |
BUY
Grant, award, or other acquisition
|
Direct |
15,596
+34.71%
|
-
|
|
Jun 05
2025
|
Mansoor Raza Mirza |
BUY
Grant, award, or other acquisition
|
Direct |
15,596
+20.83%
|
-
|
|
May 30
2025
|
John J. Boniface Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,703
+2.14%
|
$3,703
$1.33 P/Share
|
|
May 30
2025
|
Benjamin Jackson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,703
+2.67%
|
$3,703
$1.33 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 533K shares |
|---|---|
| Exercise of conversion of derivative security | 37.5K shares |
| Open market or private sale | 411K shares |
|---|